Skip to content
Triangle logo TriangleGet started
← Back to this collection

LABELS · 6ea8b135-ac8a-4a01-9b3e-0440562af45c

KENALOG-40

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date
2023-01-01
Captured
2026-09-09T23:37:51.659493+00:00
Current indication reconciliation
Not reconciled

Indications and usage: exact source text

  1. INDICATIONS AND USAGE Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tissue administration of Kenalog-40 Injection is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis, or osteoarthritis.
Full extracted label fields
application numbers
  1. NDA014901
boxed warning exact
    brand names
    1. KENALOG-40
    current indication status
    not_reconciled
    dailymed set url
    https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ed85825-cd03-4b5b-9c9a-946653b5f71a
    generic names
    1. TRIAMCINOLONE ACETONIDE
    id
    6ea8b135-ac8a-4a01-9b3e-0440562af45c
    indications and usage exact
    1. INDICATIONS AND USAGE Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tissue administration of Kenalog-40 Injection is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis, or osteoarthritis.
    indications and usage tables exact
      is original packager
        manufacturer names
        1. Proficient Rx LP
        matched search terms
        1. cancer
        2. lymphomas
        3. tumor
        package ndcs
        1. 63187-661-01
        product ndcs
        1. 63187-661
        product types
        1. HUMAN PRESCRIPTION DRUG
        recent major changes exact
          record type
          complete_spl_indications_section_candidate
          routes
          1. INTRA-ARTICULAR
          2. INTRAMUSCULAR
          rxcuis
          1. 1085754
          2. 1085756
          source batch
          file
          /private/tmp/cancer-full-research/indications/raw/labels-00400.json
          meta
          disclaimer
          Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
          last updated
          2026-09-09
          results
          limit
          100
          skip
          400
          total
          830
          sha256
          a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
          url
          https://api.fda.gov/drug/label.json?search=%28indications_and_usage%3Acancer+OR+indications_and_usage%3Acarcinoma+OR+indications_and_usage%3Acarcinomas+OR+indications_and_usage%3Alymphoma+OR+indications_and_usage%3Alymphomas+OR+indications_and_usage%3Aleukemia+OR+indications_and_usage%3Aleukaemia+OR+indications_and_usage%3Asarcoma+OR+indications_and_usage%3Asarcomas+OR+indications_and_usage%3Amelanoma+OR+indications_and_usage%3Amyeloma+OR+indications_and_usage%3Atumor+OR+indications_and_usage%3Atumors+OR+indications_and_usage%3Atumour+OR+indications_and_usage%3Atumours+OR+indications_and_usage%3Aneoplasm+OR+indications_and_usage%3Aneoplasms+OR+indications_and_usage%3Amalignant+OR+indications_and_usage%3Amalignancy+OR+indications_and_usage%3Amyelodysplastic+OR+indications_and_usage%3Amyelofibrosis+OR+indications_and_usage%3Amastocytosis+OR+indications_and_usage%3Aglioma+OR+indications_and_usage%3Aglioblastoma+OR+indications_and_usage%3Aneuroblastoma+OR+indications_and_usage%3Aretinoblastoma+OR+indications_and_usage%3Apheochromocytoma+OR+indications_and_usage%3Aparaganglioma+OR+indications_and_usage%3Amyeloproliferative+OR+indications_and_usage%3Awaldenstrom+OR+indications_and_usage%3Apolycythemia+OR+indications_and_usage%3Athrombocythemia+OR+indications_and_usage%3Adesmoid+OR+indications_and_usage%3Aneurofibromatosis+OR+indications_and_usage%3Ahistiocytosis%29+AND+%28openfda.application_number%3ANDA%2A+OR+openfda.application_number%3ABLA%2A%29&limit=100&skip=400&sort=id%3Aasc
          source url
          https://api.fda.gov/drug/label.json?search=id%3A%226ea8b135-ac8a-4a01-9b3e-0440562af45c%22
          spl effective date
          2023-01-01
          spl effective time
          20230101
          spl set id
          1ed85825-cd03-4b5b-9c9a-946653b5f71a
          spl version
          5
          substance names
          1. TRIAMCINOLONE ACETONIDE
          uniis
          1. F446C597KA
          verification flags
          1. oncology_keyword_candidate_not_clinically_classified
          2. spl_text_not_verified_identical_to_latest_approved_label
          3. individual_indications_not_split_or_reconciled
          4. not_identified_as_original_packager
          5. fda_label_posted_after_spl_effective_date_requires_version_review
          Drugs@FDA application source records
          1. application number
            NDA014901
            payload
            all indexed label documents
            1. Appl No
              014901
              Application Docs Date
              2006-11-22 00:00:00
              Application Docs ID
              10850
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              34
              Submission Type
              SUPPL
            2. Appl No
              014901
              Application Docs Date
              2010-02-04 00:00:00
              Application Docs ID
              10851
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              37
              Submission Type
              SUPPL
            3. Appl No
              014901
              Application Docs Date
              2014-07-09 00:00:00
              Application Docs ID
              10852
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              42
              Submission Type
              SUPPL
            4. Appl No
              014901
              Application Docs Date
              2011-06-16 00:00:00
              Application Docs ID
              33127
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              38
              Submission Type
              SUPPL
            5. Appl No
              014901
              Application Docs Date
              2011-07-18 00:00:00
              Application Docs ID
              33128
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              39
              Submission Type
              SUPPL
            6. Appl No
              014901
              Application Docs Date
              2018-04-01 00:00:00
              Application Docs ID
              53573
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              44
              Submission Type
              SUPPL
            7. Appl No
              014901
              Application Docs Date
              2018-06-28 00:00:00
              Application Docs ID
              54712
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              45
              Submission Type
              SUPPL
            8. Appl No
              014901
              Application Docs Date
              2020-05-19 00:00:00
              Application Docs ID
              63087
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              47
              Submission Type
              SUPPL
            9. Appl No
              014901
              Application Docs Date
              2024-06-06 00:00:00
              Application Docs ID
              78680
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              54
              Submission Type
              SUPPL
            10. Appl No
              014901
              Application Docs Date
              2024-11-18 00:00:00
              Application Docs ID
              80226
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              55
              Submission Type
              SUPPL
            all submission records
            1. Appl No
              014901
              Review Priority
              N/A
              Submission Class Code ID
              4
              Submission No
              55
              Submission Status
              AP
              Submission Status Date
              2024-08-09 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            2. Appl No
              014901
              Review Priority
              STANDARD
              Submission Class Code ID
              3
              Submission No
              54
              Submission Status
              AP
              Submission Status Date
              2024-06-05 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            3. Appl No
              014901
              Review Priority
              STANDARD
              Submission Class Code ID
              4
              Submission No
              47
              Submission Status
              AP
              Submission Status Date
              2019-04-12 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            4. Appl No
              014901
              Review Priority
              STANDARD
              Submission Class Code ID
              3
              Submission No
              45
              Submission Status
              AP
              Submission Status Date
              2018-06-22 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            5. Appl No
              014901
              Review Priority
              STANDARD
              Submission Class Code ID
              3
              Submission No
              44
              Submission Status
              AP
              Submission Status Date
              2018-03-29 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            6. Appl No
              014901
              Review Priority
              STANDARD
              Submission Class Code ID
              4
              Submission No
              43
              Submission Status
              AP
              Submission Status Date
              2015-10-26 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            7. Appl No
              014901
              Review Priority
              STANDARD
              Submission Class Code ID
              3
              Submission No
              42
              Submission Status
              AP
              Submission Status Date
              2014-07-03 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            8. Appl No
              014901
              Review Priority
              UNKNOWN
              Submission Class Code ID
              3
              Submission No
              39
              Submission Status
              AP
              Submission Status Date
              2011-07-15 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            9. Appl No
              014901
              Review Priority
              UNKNOWN
              Submission Class Code ID
              3
              Submission No
              38
              Submission Status
              AP
              Submission Status Date
              2011-06-16 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            10. Appl No
              014901
              Review Priority
              STANDARD
              Submission Class Code ID
              3
              Submission No
              37
              Submission Status
              AP
              Submission Status Date
              2010-01-28 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            11. Appl No
              014901
              Review Priority
              STANDARD
              Submission Class Code ID
              4
              Submission No
              35
              Submission Status
              AP
              Submission Status Date
              2001-01-05 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            12. Appl No
              014901
              Review Priority
              STANDARD
              Submission Class Code ID
              3
              Submission No
              34
              Submission Status
              AP
              Submission Status Date
              2006-11-20 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            application number
            NDA014901
            approval interpretation
            Application linkage and approved submission are not indication-level current approval verification
            current indication status
            not_reconciled
            has approved submission record
            true
            latest approved submission date
            2024-08-09
            latest label selection rule
            max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
            latest posted label documents
            1. Appl No
              014901
              Application Docs Date
              2024-11-18 00:00:00
              Application Docs ID
              80226
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              55
              Submission Type
              SUPPL
            official application record
            Appl No
            014901
            Appl Public Notes
            Appl Type
            NDA
            Sponsor Name
            APOTHECON
            openfda application present
            true
            products
            1. Active Ingredient
              TRIAMCINOLONE ACETONIDE
              Appl No
              014901
              Drug Name
              KENALOG-40
              Form
              INJECTABLE;INJECTION
              Product No
              001
              Reference Drug
              1
              Reference Standard
              1
              Strength
              40MG/ML
              marketing status
              1. Prescription
            2. Active Ingredient
              TRIAMCINOLONE ACETONIDE
              Appl No
              014901
              Drug Name
              KENALOG-80
              Form
              INJECTABLE;INJECTION
              Product No
              002
              Reference Drug
              1
              Reference Standard
              1
              Strength
              80MG/ML
              marketing status
              1. Prescription

          Source passages and status connections

          Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

          Passage 1 · indication intro context
          application numbers
          1. NDA014901
          brand names
          1. KENALOG-40
          classification reasons
          1. explicit_positive_indication_predicate
          2. no_tumor_directed_keyword_in_positive_statement
          3. incomplete_colon_led_indication_intro
          clinical review status
          pending
          content role
          indication_intro_context
          context span
          end
          730
          end exclusive
          true
          exact text
          INDICATIONS AND USAGE Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or
          label id
          6ea8b135-ac8a-4a01-9b3e-0440562af45c
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
          start
          0
          current approval status
          not_reconciled
          duplicate text group
          dup-58323d228f6916da1d45
          extraction review status
          automated_candidate_pending_source_review
          generic names
          1. TRIAMCINOLONE ACETONIDE
          id
          ind-span-d44a511565ba3bfccfa8
          label id
          6ea8b135-ac8a-4a01-9b3e-0440562af45c
          positive predicate support span
          end
          203
          end exclusive
          true
          exact text
          is indicated
          label id
          6ea8b135-ac8a-4a01-9b3e-0440562af45c
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
          start
          191
          qualifier mentions
            regulatory links
              schema version
              0.1.0
              source batch sha256
              a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
              source defined aliases
                source span
                end
                530
                end exclusive
                true
                exact text
                INDICATIONS AND USAGE Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions.
                label id
                6ea8b135-ac8a-4a01-9b3e-0440562af45c
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                start
                0
                source url
                https://api.fda.gov/drug/label.json?search=id%3A%226ea8b135-ac8a-4a01-9b3e-0440562af45c%22
                spl effective date
                2023-01-01
                spl set id
                1ed85825-cd03-4b5b-9c9a-946653b5f71a
                spl version
                5
                structured fields status
                not_extracted_no_values_inferred_from_mentions
                structured indication
                age
                Source null
                approval pathway
                Source null
                biomarker and test
                Source null
                disease stage
                Source null
                limitations
                Source null
                line
                Source null
                prior therapy
                Source null
                regimen
                Source null
                tumor histology
                Source null
                use intent
                not_applicable
                Passage 2 · unclassified context
                application numbers
                1. NDA014901
                brand names
                1. KENALOG-40
                classification reasons
                1. no_unambiguous_positive_indication_predicate
                clinical review status
                pending
                content role
                unclassified_context
                context span
                end
                898
                end exclusive
                true
                exact text
                ate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where a
                label id
                6ea8b135-ac8a-4a01-9b3e-0440562af45c
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                start
                331
                current approval status
                not_reconciled
                duplicate text group
                dup-48c080fac4d568aab480
                extraction review status
                automated_candidate_pending_source_review
                generic names
                1. TRIAMCINOLONE ACETONIDE
                id
                ind-span-118f3514e80166e9d431
                label id
                6ea8b135-ac8a-4a01-9b3e-0440562af45c
                positive predicate support span
                Source null
                qualifier mentions
                  regulatory links
                    schema version
                    0.1.0
                    source batch sha256
                    a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                    source defined aliases
                      source span
                      end
                      698
                      end exclusive
                      true
                      exact text
                      Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
                      label id
                      6ea8b135-ac8a-4a01-9b3e-0440562af45c
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                      start
                      531
                      source url
                      https://api.fda.gov/drug/label.json?search=id%3A%226ea8b135-ac8a-4a01-9b3e-0440562af45c%22
                      spl effective date
                      2023-01-01
                      spl set id
                      1ed85825-cd03-4b5b-9c9a-946653b5f71a
                      spl version
                      5
                      structured fields status
                      not_extracted_no_values_inferred_from_mentions
                      structured indication
                      age
                      Source null
                      approval pathway
                      Source null
                      biomarker and test
                      Source null
                      disease stage
                      Source null
                      limitations
                      Source null
                      line
                      Source null
                      prior therapy
                      Source null
                      regimen
                      Source null
                      tumor histology
                      Source null
                      use intent
                      unclear
                      Passage 3 · unclassified context
                      application numbers
                      1. NDA014901
                      brand names
                      1. KENALOG-40
                      classification reasons
                      1. no_unambiguous_positive_indication_predicate
                      clinical review status
                      pending
                      content role
                      unclassified_context
                      context span
                      end
                      1282
                      end exclusive
                      true
                      exact text
                      ickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamo
                      label id
                      6ea8b135-ac8a-4a01-9b3e-0440562af45c
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                      start
                      499
                      current approval status
                      not_reconciled
                      duplicate text group
                      dup-7991ece29c7200458eb8
                      extraction review status
                      automated_candidate_pending_source_review
                      generic names
                      1. TRIAMCINOLONE ACETONIDE
                      id
                      ind-span-327d4de9f6790e88c951
                      label id
                      6ea8b135-ac8a-4a01-9b3e-0440562af45c
                      positive predicate support span
                      Source null
                      qualifier mentions
                        regulatory links
                          schema version
                          0.1.0
                          source batch sha256
                          a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                          source defined aliases
                            source span
                            end
                            1082
                            end exclusive
                            true
                            exact text
                            Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
                            label id
                            6ea8b135-ac8a-4a01-9b3e-0440562af45c
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                            start
                            699
                            source url
                            https://api.fda.gov/drug/label.json?search=id%3A%226ea8b135-ac8a-4a01-9b3e-0440562af45c%22
                            spl effective date
                            2023-01-01
                            spl set id
                            1ed85825-cd03-4b5b-9c9a-946653b5f71a
                            spl version
                            5
                            structured fields status
                            not_extracted_no_values_inferred_from_mentions
                            structured indication
                            age
                            Source null
                            approval pathway
                            Source null
                            biomarker and test
                            Source null
                            disease stage
                            Source null
                            limitations
                            Source null
                            line
                            Source null
                            prior therapy
                            Source null
                            regimen
                            Source null
                            tumor histology
                            Source null
                            use intent
                            unclear
                            Passage 4 · unclassified context
                            application numbers
                            1. NDA014901
                            brand names
                            1. KENALOG-40
                            classification reasons
                            1. no_unambiguous_positive_indication_predicate
                            clinical review status
                            pending
                            content role
                            unclassified_context
                            context span
                            end
                            1413
                            end exclusive
                            true
                            exact text
                            ticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic
                            label id
                            6ea8b135-ac8a-4a01-9b3e-0440562af45c
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                            start
                            883
                            current approval status
                            not_reconciled
                            duplicate text group
                            dup-b158d6bc5bbfbb2d8693
                            extraction review status
                            automated_candidate_pending_source_review
                            generic names
                            1. TRIAMCINOLONE ACETONIDE
                            id
                            ind-span-3dd24dabc24a07789bfc
                            label id
                            6ea8b135-ac8a-4a01-9b3e-0440562af45c
                            positive predicate support span
                            Source null
                            qualifier mentions
                              regulatory links
                                schema version
                                0.1.0
                                source batch sha256
                                a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                source defined aliases
                                  source span
                                  end
                                  1213
                                  end exclusive
                                  true
                                  exact text
                                  Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis.
                                  label id
                                  6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                                  start
                                  1083
                                  source url
                                  https://api.fda.gov/drug/label.json?search=id%3A%226ea8b135-ac8a-4a01-9b3e-0440562af45c%22
                                  spl effective date
                                  2023-01-01
                                  spl set id
                                  1ed85825-cd03-4b5b-9c9a-946653b5f71a
                                  spl version
                                  5
                                  structured fields status
                                  not_extracted_no_values_inferred_from_mentions
                                  structured indication
                                  age
                                  Source null
                                  approval pathway
                                  Source null
                                  biomarker and test
                                  Source null
                                  disease stage
                                  Source null
                                  limitations
                                  Source null
                                  line
                                  Source null
                                  prior therapy
                                  Source null
                                  regimen
                                  Source null
                                  tumor histology
                                  Source null
                                  use intent
                                  unclear
                                  Passage 5 · unclassified context
                                  application numbers
                                  1. NDA014901
                                  brand names
                                  1. KENALOG-40
                                  classification reasons
                                  1. no_unambiguous_positive_indication_predicate
                                  clinical review status
                                  pending
                                  content role
                                  unclassified_context
                                  context span
                                  end
                                  1570
                                  end exclusive
                                  true
                                  exact text
                                  a, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neopla
                                  label id
                                  6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                                  start
                                  1014
                                  current approval status
                                  not_reconciled
                                  duplicate text group
                                  dup-69289b9fa2d40069e5ee
                                  extraction review status
                                  automated_candidate_pending_source_review
                                  generic names
                                  1. TRIAMCINOLONE ACETONIDE
                                  id
                                  ind-span-08f3c235fb927a3270b7
                                  label id
                                  6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                  positive predicate support span
                                  Source null
                                  qualifier mentions
                                    regulatory links
                                      schema version
                                      0.1.0
                                      source batch sha256
                                      a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                      source defined aliases
                                        source span
                                        end
                                        1370
                                        end exclusive
                                        true
                                        exact text
                                        Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia.
                                        label id
                                        6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                                        start
                                        1214
                                        source url
                                        https://api.fda.gov/drug/label.json?search=id%3A%226ea8b135-ac8a-4a01-9b3e-0440562af45c%22
                                        spl effective date
                                        2023-01-01
                                        spl set id
                                        1ed85825-cd03-4b5b-9c9a-946653b5f71a
                                        spl version
                                        5
                                        structured fields status
                                        not_extracted_no_values_inferred_from_mentions
                                        structured indication
                                        age
                                        Source null
                                        approval pathway
                                        Source null
                                        biomarker and test
                                        Source null
                                        disease stage
                                        Source null
                                        limitations
                                        Source null
                                        line
                                        Source null
                                        prior therapy
                                        Source null
                                        regimen
                                        Source null
                                        tumor histology
                                        Source null
                                        use intent
                                        unclear
                                        Passage 6 · unclassified context
                                        application numbers
                                        1. NDA014901
                                        brand names
                                        1. KENALOG-40
                                        classification reasons
                                        1. no_unambiguous_positive_indication_predicate
                                        clinical review status
                                        pending
                                        content role
                                        unclassified_context
                                        context span
                                        end
                                        1763
                                        end exclusive
                                        true
                                        exact text
                                        regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tu
                                        label id
                                        6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                                        start
                                        1171
                                        current approval status
                                        not_reconciled
                                        duplicate text group
                                        dup-9b5e34e522d572ac7453
                                        extraction review status
                                        automated_candidate_pending_source_review
                                        generic names
                                        1. TRIAMCINOLONE ACETONIDE
                                        id
                                        ind-span-26b943bb9342ce6e1188
                                        label id
                                        6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                        positive predicate support span
                                        Source null
                                        qualifier mentions
                                          regulatory links
                                            schema version
                                            0.1.0
                                            source batch sha256
                                            a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                            source defined aliases
                                              source span
                                              end
                                              1563
                                              end exclusive
                                              true
                                              exact text
                                              Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.
                                              label id
                                              6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                              offset unit
                                              unicode_code_points
                                              source array index
                                              0
                                              source field
                                              indications_and_usage_exact
                                              source text sha256
                                              89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                                              start
                                              1371
                                              source url
                                              https://api.fda.gov/drug/label.json?search=id%3A%226ea8b135-ac8a-4a01-9b3e-0440562af45c%22
                                              spl effective date
                                              2023-01-01
                                              spl set id
                                              1ed85825-cd03-4b5b-9c9a-946653b5f71a
                                              spl version
                                              5
                                              structured fields status
                                              not_extracted_no_values_inferred_from_mentions
                                              structured indication
                                              age
                                              Source null
                                              approval pathway
                                              Source null
                                              biomarker and test
                                              Source null
                                              disease stage
                                              Source null
                                              limitations
                                              Source null
                                              line
                                              Source null
                                              prior therapy
                                              Source null
                                              regimen
                                              Source null
                                              tumor histology
                                              Source null
                                              use intent
                                              unclear
                                              Passage 7 · unclassified context
                                              application numbers
                                              1. NDA014901
                                              brand names
                                              1. KENALOG-40
                                              classification reasons
                                              1. no_unambiguous_positive_indication_predicate
                                              clinical review status
                                              pending
                                              content role
                                              unclassified_context
                                              context span
                                              end
                                              1842
                                              end exclusive
                                              true
                                              exact text
                                              penia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteri
                                              label id
                                              6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                              offset unit
                                              unicode_code_points
                                              source array index
                                              0
                                              source field
                                              indications_and_usage_exact
                                              source text sha256
                                              89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                                              start
                                              1364
                                              current approval status
                                              not_reconciled
                                              duplicate text group
                                              dup-686abb2877e3e9885128
                                              extraction review status
                                              automated_candidate_pending_source_review
                                              generic names
                                              1. TRIAMCINOLONE ACETONIDE
                                              id
                                              ind-span-ff418105047bf5c06165
                                              label id
                                              6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                              positive predicate support span
                                              Source null
                                              qualifier mentions
                                                regulatory links
                                                  schema version
                                                  0.1.0
                                                  source batch sha256
                                                  a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                                  source defined aliases
                                                    source span
                                                    end
                                                    1642
                                                    end exclusive
                                                    true
                                                    exact text
                                                    Neoplastic diseases: For the palliative management of leukemias and lymphomas.
                                                    label id
                                                    6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                                    offset unit
                                                    unicode_code_points
                                                    source array index
                                                    0
                                                    source field
                                                    indications_and_usage_exact
                                                    source text sha256
                                                    89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                                                    start
                                                    1564
                                                    source url
                                                    https://api.fda.gov/drug/label.json?search=id%3A%226ea8b135-ac8a-4a01-9b3e-0440562af45c%22
                                                    spl effective date
                                                    2023-01-01
                                                    spl set id
                                                    1ed85825-cd03-4b5b-9c9a-946653b5f71a
                                                    spl version
                                                    5
                                                    structured fields status
                                                    not_extracted_no_values_inferred_from_mentions
                                                    structured indication
                                                    age
                                                    Source null
                                                    approval pathway
                                                    Source null
                                                    biomarker and test
                                                    Source null
                                                    disease stage
                                                    Source null
                                                    limitations
                                                    Source null
                                                    line
                                                    Source null
                                                    prior therapy
                                                    Source null
                                                    regimen
                                                    Source null
                                                    tumor histology
                                                    Source null
                                                    use intent
                                                    unclear
                                                    Passage 8 · unclassified context
                                                    application numbers
                                                    1. NDA014901
                                                    brand names
                                                    1. KENALOG-40
                                                    classification reasons
                                                    1. no_unambiguous_positive_indication_predicate
                                                    clinical review status
                                                    pending
                                                    content role
                                                    unclassified_context
                                                    context span
                                                    end
                                                    1981
                                                    end exclusive
                                                    true
                                                    exact text
                                                    berculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission o
                                                    label id
                                                    6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                                    offset unit
                                                    unicode_code_points
                                                    source array index
                                                    0
                                                    source field
                                                    indications_and_usage_exact
                                                    source text sha256
                                                    89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                                                    start
                                                    1443
                                                    current approval status
                                                    not_reconciled
                                                    duplicate text group
                                                    dup-986e254badc64ae268fd
                                                    extraction review status
                                                    automated_candidate_pending_source_review
                                                    generic names
                                                    1. TRIAMCINOLONE ACETONIDE
                                                    id
                                                    ind-span-aa76d949fd7dc091c022
                                                    label id
                                                    6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                                    positive predicate support span
                                                    Source null
                                                    qualifier mentions
                                                    1. context exact
                                                      ltiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
                                                      kind
                                                      biomarker
                                                      polarity
                                                      not_inferred
                                                      span
                                                      end
                                                      1780
                                                      end exclusive
                                                      true
                                                      exact text
                                                      metastatic brain tumor or craniotomy
                                                      label id
                                                      6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                                      offset unit
                                                      unicode_code_points
                                                      source array index
                                                      0
                                                      source field
                                                      indications_and_usage_exact
                                                      source text sha256
                                                      89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                                                      start
                                                      1744
                                                    2. context exact
                                                      ltiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
                                                      kind
                                                      stage_or_setting
                                                      polarity
                                                      not_inferred
                                                      span
                                                      end
                                                      1780
                                                      end exclusive
                                                      true
                                                      exact text
                                                      metastatic brain tumor or craniotomy
                                                      label id
                                                      6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                                      offset unit
                                                      unicode_code_points
                                                      source array index
                                                      0
                                                      source field
                                                      indications_and_usage_exact
                                                      source text sha256
                                                      89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                                                      start
                                                      1744
                                                    regulatory links
                                                      schema version
                                                      0.1.0
                                                      source batch sha256
                                                      a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                                      source defined aliases
                                                        source span
                                                        end
                                                        1781
                                                        end exclusive
                                                        true
                                                        exact text
                                                        Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
                                                        label id
                                                        6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                                        offset unit
                                                        unicode_code_points
                                                        source array index
                                                        0
                                                        source field
                                                        indications_and_usage_exact
                                                        source text sha256
                                                        89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                                                        start
                                                        1643
                                                        source url
                                                        https://api.fda.gov/drug/label.json?search=id%3A%226ea8b135-ac8a-4a01-9b3e-0440562af45c%22
                                                        spl effective date
                                                        2023-01-01
                                                        spl set id
                                                        1ed85825-cd03-4b5b-9c9a-946653b5f71a
                                                        spl version
                                                        5
                                                        structured fields status
                                                        not_extracted_no_values_inferred_from_mentions
                                                        structured indication
                                                        age
                                                        Source null
                                                        approval pathway
                                                        Source null
                                                        biomarker and test
                                                        Source null
                                                        disease stage
                                                        Source null
                                                        limitations
                                                        Source null
                                                        line
                                                        Source null
                                                        prior therapy
                                                        Source null
                                                        regimen
                                                        Source null
                                                        tumor histology
                                                        Source null
                                                        use intent
                                                        unclear
                                                        Passage 9 · unclassified context
                                                        application numbers
                                                        1. NDA014901
                                                        brand names
                                                        1. KENALOG-40
                                                        classification reasons
                                                        1. no_unambiguous_positive_indication_predicate
                                                        clinical review status
                                                        pending
                                                        content role
                                                        unclassified_context
                                                        context span
                                                        end
                                                        2131
                                                        end exclusive
                                                        true
                                                        exact text
                                                        s: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulm
                                                        label id
                                                        6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                                        offset unit
                                                        unicode_code_points
                                                        source array index
                                                        0
                                                        source field
                                                        indications_and_usage_exact
                                                        source text sha256
                                                        89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                                                        start
                                                        1582
                                                        current approval status
                                                        not_reconciled
                                                        duplicate text group
                                                        dup-8ea8ba55b97209909416
                                                        extraction review status
                                                        automated_candidate_pending_source_review
                                                        generic names
                                                        1. TRIAMCINOLONE ACETONIDE
                                                        id
                                                        ind-span-b7df986826fcac4fe2cd
                                                        label id
                                                        6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                                        positive predicate support span
                                                        Source null
                                                        qualifier mentions
                                                          regulatory links
                                                            schema version
                                                            0.1.0
                                                            source batch sha256
                                                            a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                                            source defined aliases
                                                              source span
                                                              end
                                                              1931
                                                              end exclusive
                                                              true
                                                              exact text
                                                              Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.
                                                              label id
                                                              6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                                              offset unit
                                                              unicode_code_points
                                                              source array index
                                                              0
                                                              source field
                                                              indications_and_usage_exact
                                                              source text sha256
                                                              89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                                                              start
                                                              1782
                                                              source url
                                                              https://api.fda.gov/drug/label.json?search=id%3A%226ea8b135-ac8a-4a01-9b3e-0440562af45c%22
                                                              spl effective date
                                                              2023-01-01
                                                              spl set id
                                                              1ed85825-cd03-4b5b-9c9a-946653b5f71a
                                                              spl version
                                                              5
                                                              structured fields status
                                                              not_extracted_no_values_inferred_from_mentions
                                                              structured indication
                                                              age
                                                              Source null
                                                              approval pathway
                                                              Source null
                                                              biomarker and test
                                                              Source null
                                                              disease stage
                                                              Source null
                                                              limitations
                                                              Source null
                                                              line
                                                              Source null
                                                              prior therapy
                                                              Source null
                                                              regimen
                                                              Source null
                                                              tumor histology
                                                              Source null
                                                              use intent
                                                              unclear
                                                              Passage 10 · unclassified context
                                                              application numbers
                                                              1. NDA014901
                                                              brand names
                                                              1. KENALOG-40
                                                              classification reasons
                                                              1. no_unambiguous_positive_indication_predicate
                                                              clinical review status
                                                              pending
                                                              content role
                                                              unclassified_context
                                                              context span
                                                              end
                                                              2263
                                                              end exclusive
                                                              true
                                                              exact text
                                                              primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptom
                                                              label id
                                                              6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                                              offset unit
                                                              unicode_code_points
                                                              source array index
                                                              0
                                                              source field
                                                              indications_and_usage_exact
                                                              source text sha256
                                                              89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                                                              start
                                                              1732
                                                              current approval status
                                                              not_reconciled
                                                              duplicate text group
                                                              dup-222e853f6cf2d7c3766a
                                                              extraction review status
                                                              automated_candidate_pending_source_review
                                                              generic names
                                                              1. TRIAMCINOLONE ACETONIDE
                                                              id
                                                              ind-span-693a87a96f6a8ac40659
                                                              label id
                                                              6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                                              positive predicate support span
                                                              Source null
                                                              qualifier mentions
                                                                regulatory links
                                                                  schema version
                                                                  0.1.0
                                                                  source batch sha256
                                                                  a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                                                  source defined aliases
                                                                    source span
                                                                    end
                                                                    2063
                                                                    end exclusive
                                                                    true
                                                                    exact text
                                                                    Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.
                                                                    label id
                                                                    6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                                                    offset unit
                                                                    unicode_code_points
                                                                    source array index
                                                                    0
                                                                    source field
                                                                    indications_and_usage_exact
                                                                    source text sha256
                                                                    89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                                                                    start
                                                                    1932
                                                                    source url
                                                                    https://api.fda.gov/drug/label.json?search=id%3A%226ea8b135-ac8a-4a01-9b3e-0440562af45c%22
                                                                    spl effective date
                                                                    2023-01-01
                                                                    spl set id
                                                                    1ed85825-cd03-4b5b-9c9a-946653b5f71a
                                                                    spl version
                                                                    5
                                                                    structured fields status
                                                                    not_extracted_no_values_inferred_from_mentions
                                                                    structured indication
                                                                    age
                                                                    Source null
                                                                    approval pathway
                                                                    Source null
                                                                    biomarker and test
                                                                    Source null
                                                                    disease stage
                                                                    Source null
                                                                    limitations
                                                                    Source null
                                                                    line
                                                                    Source null
                                                                    prior therapy
                                                                    Source null
                                                                    regimen
                                                                    Source null
                                                                    tumor histology
                                                                    Source null
                                                                    use intent
                                                                    unclear
                                                                    Passage 11 · unclassified context
                                                                    application numbers
                                                                    1. NDA014901
                                                                    brand names
                                                                    1. KENALOG-40
                                                                    classification reasons
                                                                    1. no_unambiguous_positive_indication_predicate
                                                                    clinical review status
                                                                    pending
                                                                    content role
                                                                    unclassified_context
                                                                    context span
                                                                    end
                                                                    2480
                                                                    end exclusive
                                                                    true
                                                                    exact text
                                                                    ar inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spo
                                                                    label id
                                                                    6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                                                    offset unit
                                                                    unicode_code_points
                                                                    source array index
                                                                    0
                                                                    source field
                                                                    indications_and_usage_exact
                                                                    source text sha256
                                                                    89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                                                                    start
                                                                    1864
                                                                    current approval status
                                                                    not_reconciled
                                                                    duplicate text group
                                                                    dup-3796f0f1d72e8e1510a8
                                                                    extraction review status
                                                                    automated_candidate_pending_source_review
                                                                    generic names
                                                                    1. TRIAMCINOLONE ACETONIDE
                                                                    id
                                                                    ind-span-039df7ea20b14d6805fd
                                                                    label id
                                                                    6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                                                    positive predicate support span
                                                                    Source null
                                                                    qualifier mentions
                                                                      regulatory links
                                                                        schema version
                                                                        0.1.0
                                                                        source batch sha256
                                                                        a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                                                        source defined aliases
                                                                          source span
                                                                          end
                                                                          2280
                                                                          end exclusive
                                                                          true
                                                                          exact text
                                                                          Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
                                                                          label id
                                                                          6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                                                          offset unit
                                                                          unicode_code_points
                                                                          source array index
                                                                          0
                                                                          source field
                                                                          indications_and_usage_exact
                                                                          source text sha256
                                                                          89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                                                                          start
                                                                          2064
                                                                          source url
                                                                          https://api.fda.gov/drug/label.json?search=id%3A%226ea8b135-ac8a-4a01-9b3e-0440562af45c%22
                                                                          spl effective date
                                                                          2023-01-01
                                                                          spl set id
                                                                          1ed85825-cd03-4b5b-9c9a-946653b5f71a
                                                                          spl version
                                                                          5
                                                                          structured fields status
                                                                          not_extracted_no_values_inferred_from_mentions
                                                                          structured indication
                                                                          age
                                                                          Source null
                                                                          approval pathway
                                                                          Source null
                                                                          biomarker and test
                                                                          Source null
                                                                          disease stage
                                                                          Source null
                                                                          limitations
                                                                          Source null
                                                                          line
                                                                          Source null
                                                                          prior therapy
                                                                          Source null
                                                                          regimen
                                                                          Source null
                                                                          tumor histology
                                                                          Source null
                                                                          use intent
                                                                          unclear
                                                                          Passage 12 · unclassified context
                                                                          application numbers
                                                                          1. NDA014901
                                                                          brand names
                                                                          1. KENALOG-40
                                                                          classification reasons
                                                                          1. no_unambiguous_positive_indication_predicate
                                                                          clinical review status
                                                                          pending
                                                                          content role
                                                                          unclassified_context
                                                                          context span
                                                                          end
                                                                          2831
                                                                          end exclusive
                                                                          true
                                                                          exact text
                                                                          ses: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tissue administration of Kenalog-40 Injection is indicated as adjunct
                                                                          label id
                                                                          6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                                                          offset unit
                                                                          unicode_code_points
                                                                          source array index
                                                                          0
                                                                          source field
                                                                          indications_and_usage_exact
                                                                          source text sha256
                                                                          89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                                                                          start
                                                                          2081
                                                                          current approval status
                                                                          not_reconciled
                                                                          duplicate text group
                                                                          dup-73c1f62035e4ff1f3cac
                                                                          extraction review status
                                                                          automated_candidate_pending_source_review
                                                                          generic names
                                                                          1. TRIAMCINOLONE ACETONIDE
                                                                          id
                                                                          ind-span-fa206c138e720c347910
                                                                          label id
                                                                          6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                                                          positive predicate support span
                                                                          Source null
                                                                          qualifier mentions
                                                                            regulatory links
                                                                              schema version
                                                                              0.1.0
                                                                              source batch sha256
                                                                              a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                                                              source defined aliases
                                                                                source span
                                                                                end
                                                                                2631
                                                                                end exclusive
                                                                                true
                                                                                exact text
                                                                                Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).
                                                                                label id
                                                                                6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                                                                offset unit
                                                                                unicode_code_points
                                                                                source array index
                                                                                0
                                                                                source field
                                                                                indications_and_usage_exact
                                                                                source text sha256
                                                                                89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                                                                                start
                                                                                2281
                                                                                source url
                                                                                https://api.fda.gov/drug/label.json?search=id%3A%226ea8b135-ac8a-4a01-9b3e-0440562af45c%22
                                                                                spl effective date
                                                                                2023-01-01
                                                                                spl set id
                                                                                1ed85825-cd03-4b5b-9c9a-946653b5f71a
                                                                                spl version
                                                                                5
                                                                                structured fields status
                                                                                not_extracted_no_values_inferred_from_mentions
                                                                                structured indication
                                                                                age
                                                                                Source null
                                                                                approval pathway
                                                                                Source null
                                                                                biomarker and test
                                                                                Source null
                                                                                disease stage
                                                                                Source null
                                                                                limitations
                                                                                Source null
                                                                                line
                                                                                Source null
                                                                                prior therapy
                                                                                Source null
                                                                                regimen
                                                                                Source null
                                                                                tumor histology
                                                                                Source null
                                                                                use intent
                                                                                unclear
                                                                                Passage 13 · unclassified context
                                                                                application numbers
                                                                                1. NDA014901
                                                                                brand names
                                                                                1. KENALOG-40
                                                                                classification reasons
                                                                                1. no_unambiguous_positive_indication_predicate
                                                                                clinical review status
                                                                                pending
                                                                                content role
                                                                                unclassified_context
                                                                                context span
                                                                                end
                                                                                2917
                                                                                end exclusive
                                                                                true
                                                                                exact text
                                                                                hritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tissue administration of Kenalog-40 Injection is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode o
                                                                                label id
                                                                                6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                                                                offset unit
                                                                                unicode_code_points
                                                                                source array index
                                                                                0
                                                                                source field
                                                                                indications_and_usage_exact
                                                                                source text sha256
                                                                                89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                                                                                start
                                                                                2432
                                                                                current approval status
                                                                                not_reconciled
                                                                                duplicate text group
                                                                                dup-fae83976ebe416167e95
                                                                                extraction review status
                                                                                automated_candidate_pending_source_review
                                                                                generic names
                                                                                1. TRIAMCINOLONE ACETONIDE
                                                                                id
                                                                                ind-span-60695abd304cded38718
                                                                                label id
                                                                                6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                                                                positive predicate support span
                                                                                Source null
                                                                                qualifier mentions
                                                                                  regulatory links
                                                                                    schema version
                                                                                    0.1.0
                                                                                    source batch sha256
                                                                                    a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                                                                    source defined aliases
                                                                                      source span
                                                                                      end
                                                                                      2717
                                                                                      end exclusive
                                                                                      true
                                                                                      exact text
                                                                                      For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.
                                                                                      label id
                                                                                      6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                                                                      offset unit
                                                                                      unicode_code_points
                                                                                      source array index
                                                                                      0
                                                                                      source field
                                                                                      indications_and_usage_exact
                                                                                      source text sha256
                                                                                      89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                                                                                      start
                                                                                      2632
                                                                                      source url
                                                                                      https://api.fda.gov/drug/label.json?search=id%3A%226ea8b135-ac8a-4a01-9b3e-0440562af45c%22
                                                                                      spl effective date
                                                                                      2023-01-01
                                                                                      spl set id
                                                                                      1ed85825-cd03-4b5b-9c9a-946653b5f71a
                                                                                      spl version
                                                                                      5
                                                                                      structured fields status
                                                                                      not_extracted_no_values_inferred_from_mentions
                                                                                      structured indication
                                                                                      age
                                                                                      Source null
                                                                                      approval pathway
                                                                                      Source null
                                                                                      biomarker and test
                                                                                      Source null
                                                                                      disease stage
                                                                                      Source null
                                                                                      limitations
                                                                                      Source null
                                                                                      line
                                                                                      Source null
                                                                                      prior therapy
                                                                                      Source null
                                                                                      regimen
                                                                                      Source null
                                                                                      tumor histology
                                                                                      Source null
                                                                                      use intent
                                                                                      unclear
                                                                                      Passage 14 · positive indication candidate
                                                                                      application numbers
                                                                                      1. NDA014901
                                                                                      brand names
                                                                                      1. KENALOG-40
                                                                                      classification reasons
                                                                                      1. explicit_positive_indication_predicate
                                                                                      2. no_tumor_directed_keyword_in_positive_statement
                                                                                      clinical review status
                                                                                      pending
                                                                                      content role
                                                                                      positive_indication_candidate
                                                                                      context span
                                                                                      end
                                                                                      3087
                                                                                      end exclusive
                                                                                      true
                                                                                      exact text
                                                                                      oid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tissue administration of Kenalog-40 Injection is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis, or osteoarthritis.
                                                                                      label id
                                                                                      6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                                                                      offset unit
                                                                                      unicode_code_points
                                                                                      source array index
                                                                                      0
                                                                                      source field
                                                                                      indications_and_usage_exact
                                                                                      source text sha256
                                                                                      89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                                                                                      start
                                                                                      2518
                                                                                      current approval status
                                                                                      not_reconciled
                                                                                      duplicate text group
                                                                                      dup-7e5347d3a91cfd0cf002
                                                                                      extraction review status
                                                                                      automated_candidate_pending_source_review
                                                                                      generic names
                                                                                      1. TRIAMCINOLONE ACETONIDE
                                                                                      id
                                                                                      ind-span-ab9bc030b3f01d3b3613
                                                                                      label id
                                                                                      6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                                                                      positive predicate support span
                                                                                      end
                                                                                      2820
                                                                                      end exclusive
                                                                                      true
                                                                                      exact text
                                                                                      is indicated
                                                                                      label id
                                                                                      6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                                                                      offset unit
                                                                                      unicode_code_points
                                                                                      source array index
                                                                                      0
                                                                                      source field
                                                                                      indications_and_usage_exact
                                                                                      source text sha256
                                                                                      89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                                                                                      start
                                                                                      2808
                                                                                      qualifier mentions
                                                                                        regulatory links
                                                                                          schema version
                                                                                          0.1.0
                                                                                          source batch sha256
                                                                                          a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                                                                          source defined aliases
                                                                                            source span
                                                                                            end
                                                                                            3087
                                                                                            end exclusive
                                                                                            true
                                                                                            exact text
                                                                                            Intra-Articular The intra-articular or soft tissue administration of Kenalog-40 Injection is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis, or osteoarthritis.
                                                                                            label id
                                                                                            6ea8b135-ac8a-4a01-9b3e-0440562af45c
                                                                                            offset unit
                                                                                            unicode_code_points
                                                                                            source array index
                                                                                            0
                                                                                            source field
                                                                                            indications_and_usage_exact
                                                                                            source text sha256
                                                                                            89e5153f7ae3d17cea970ecd837b9bb7a7bf98520a9536c2a0490f45efed8aca
                                                                                            start
                                                                                            2718
                                                                                            source url
                                                                                            https://api.fda.gov/drug/label.json?search=id%3A%226ea8b135-ac8a-4a01-9b3e-0440562af45c%22
                                                                                            spl effective date
                                                                                            2023-01-01
                                                                                            spl set id
                                                                                            1ed85825-cd03-4b5b-9c9a-946653b5f71a
                                                                                            spl version
                                                                                            5
                                                                                            structured fields status
                                                                                            not_extracted_no_values_inferred_from_mentions
                                                                                            structured indication
                                                                                            age
                                                                                            Source null
                                                                                            approval pathway
                                                                                            Source null
                                                                                            biomarker and test
                                                                                            Source null
                                                                                            disease stage
                                                                                            Source null
                                                                                            limitations
                                                                                            Source null
                                                                                            line
                                                                                            Source null
                                                                                            prior therapy
                                                                                            Source null
                                                                                            regimen
                                                                                            Source null
                                                                                            tumor histology
                                                                                            Source null
                                                                                            use intent
                                                                                            non_oncology_or_unclear_candidate

                                                                                            Preserved source evidence · Not medical advice